argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
03 Janvier 2022 - 7:00AM
January 3,
2022Breda, the
Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that Tim Van Hauwermeiren, Chief Executive Officer, will present at
the 40th Annual J.P. Morgan Healthcare Conference on Monday,
January 10, 2022 at 7:30 a.m. ET.
A live webcast of the presentation may be accessed on the
Investors section of the argenx website at argenx.com/investors. A
replay of the webcast will be available on the argenx website for
approximately 30 days following the presentation.
About argenxargenx is a global
immunology company committed to improving the lives of people
suffering from severe autoimmune diseases. Partnering with leading
academic researchers through its Immunology Innovation Program
(IIP), argenx aims to translate immunology breakthroughs into a
world-class portfolio of novel antibody-based medicines. argenx
developed and is commercializing the first-and-only FDA approved
neonatal Fc receptor blocker, VYVGART (efgartigimod alfa-fcab) for
the treatment of generalized myasthenia gravis (gMG) in adult
patients who are anti-acetylcholine receptor (AChR) antibody
positive. The Company is evaluating efgartigimod in multiple
serious autoimmune diseases and advancing several earlier stage
experimental medicines within its therapeutic franchises. For more
information, visit www.argenx.com and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:Kelsey KirkKKirk@argenx.com
Joke Comijn (EU)jcomijn@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
